Category Press Releases

Prothena

Prothena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value

Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics,…

Read MoreProthena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value
Sarepta Therapeutics

Sarepta Therapeutics Launches 2026-2027 Route 79 Duchenne Scholarship Program

Sarepta Supports Educational Ambitions of Duchenne Community with $5,000 Scholarships Why is supporting the education of individuals with Duchenne muscular dystrophy crucial for the future of rare disease treatment? Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases,…

Read MoreSarepta Therapeutics Launches 2026-2027 Route 79 Duchenne Scholarship Program
Evox

Evox Therapeutics Partners with RSRT to Develop Gene Editing Treatment for Rett Syndrome

Collaboration Aims to Overcome Delivery Challenges for Neurological Disorders Why has gene editing for Rett syndrome remained elusive despite its potential to reverse symptoms? Evox Therapeutics Ltd (Evox), a biotechnology company focused on developing innovative therapies for genetically driven neurodegenerative…

Read MoreEvox Therapeutics Partners with RSRT to Develop Gene Editing Treatment for Rett Syndrome
Evox

Chemify and Sanacor Partner to Accelerate Mitochondrial Dysfunction Therapies

Chemify and Sanacor Join Forces to Tackle Diabetic Cardiovascular Disease Why is the discovery of new therapies for diabetic cardiovascular disease so critical? Chemify, a deep-tech pioneer in Chemputation, and Sanacor Inc., a biotechnology company focused on mitochondrial dysfunction, have…

Read MoreChemify and Sanacor Partner to Accelerate Mitochondrial Dysfunction Therapies
Enveric Biosciences

Enveric Biosciences Secures Patent Protection Amidst Industry Challenges

Enveric Biosciences Overcomes Legal Hurdles to Protect Innovative Neuroplastogenic Therapeutics What does the withdrawal of a patent challenge mean for a biotech company’s intellectual property and future innovations? Enveric Biosciences a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics for psychiatric…

Read MoreEnveric Biosciences Secures Patent Protection Amidst Industry Challenges
IQVIA

IQVIA Acquires Charles River Laboratories’ Discovery Services to Enhance Drug Discovery Capabilities

IQVIA Strengthens Early-Stage Discovery Research with Advanced In Vitro and AI-Driven Solutions Why is the life sciences industry facing a critical need for accelerated drug discovery? IQVIA Holdings Inc. a global leader in advanced analytics, technology solutions, and clinical research…

Read MoreIQVIA Acquires Charles River Laboratories’ Discovery Services to Enhance Drug Discovery Capabilities
Enveric Biosciences

Sensei Biotherapeutics Grants Stock Options to 17 New Employees, Including COO

Strategic Move to Attract and Retain Talent in the Biotech Sector What does it take to attract top talent in the highly competitive biotech industry? Sensei Biotherapeutics, Inc. a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients,…

Read MoreSensei Biotherapeutics Grants Stock Options to 17 New Employees, Including COO
Pearl

Pearl Dental AI Solutions Partner with DECA Dental Group to Enhance Patient Care

DECA Dental Group Adopts Pearl’s AI to Improve Clinical Outcomes and Patient Engagement In the rapidly evolving landscape of dental technology, the integration of artificial intelligence (AI) is becoming a game-changer. Pearl, the global leader in dental AI solutions, has announced…

Read MorePearl Dental AI Solutions Partner with DECA Dental Group to Enhance Patient Care